Ceribell, Inc.

Ceribell, Inc. is a medical technology company that develops the Ceribell System, a point-of-care EEG platform. This system is designed to diagnose and manage patients with serious neurological conditions, particularly in acute care settings. The Ceribell System combines portable, rapidly deployable hardware with artificial intelligence (AI)-powered algorithms to enable quick diagnosis and continuous monitoring. The company's initial focus is on detecting and managing seizures in acute care, aiming to address limitations of conventional EEG systems that lead to diagnostic delays and suboptimal patient care. By making EEG more accessible and enabling continuous monitoring via AI, the Ceribell System assists clinicians in diagnosing and managing patients at risk of seizure. As of December 31, 2025, the Ceribell System has been adopted by more than 600 hospitals, including academic centers and community hospitals. Seizures are abnormal bursts of electrical activity in the brain, which can lead to permanent disability or death if untreated. While often linked to epilepsy, seizures in acute care can also be triggered by conditions such as brain tumors, traumatic brain injury, stroke, cardiac arrest, and sepsis.